vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $11.1M, roughly 1.7× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -0.8%, a 217.5% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -48.8%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
CTMX vs NREF — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $11.1M |
| Net Profit | $-154.0K | $24.0M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | 216.6% |
| Revenue YoY | -25.7% | -48.8% |
| Net Profit YoY | 97.6% | 58.7% |
| EPS (diluted) | — | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | $18.7M | $12.1M | ||
| Q1 25 | $50.9M | $11.5M | ||
| Q4 24 | $38.1M | $21.7M | ||
| Q3 24 | $33.4M | $12.5M | ||
| Q2 24 | $25.1M | $6.7M | ||
| Q1 24 | $41.5M | $-12.8M |
| Q4 25 | — | $24.0M | ||
| Q3 25 | — | $50.9M | ||
| Q2 25 | $-154.0K | $22.3M | ||
| Q1 25 | $23.5M | $26.0M | ||
| Q4 24 | $18.9M | $15.2M | ||
| Q3 24 | $5.7M | $23.3M | ||
| Q2 24 | $-6.5M | $12.1M | ||
| Q1 24 | $13.8M | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | 216.6% | ||
| Q3 25 | — | 407.0% | ||
| Q2 25 | -0.8% | 184.5% | ||
| Q1 25 | 46.2% | 225.6% | ||
| Q4 24 | 49.6% | 69.9% | ||
| Q3 24 | 17.2% | 186.4% | ||
| Q2 24 | -26.0% | 179.7% | ||
| Q1 24 | 33.3% | 114.3% |
| Q4 25 | — | $0.47 | ||
| Q3 25 | — | $1.14 | ||
| Q2 25 | — | $0.54 | ||
| Q1 25 | — | $0.70 | ||
| Q4 24 | — | $0.71 | ||
| Q3 24 | — | $0.74 | ||
| Q2 24 | — | $0.40 | ||
| Q1 24 | — | $-0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $31.1M |
| Total DebtLower is stronger | — | $771.2M |
| Stockholders' EquityBook value | $119.9M | $388.0M |
| Total Assets | $175.1M | $5.3B |
| Debt / EquityLower = less leverage | — | 1.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $49.0M | $9.1M | ||
| Q1 25 | $47.6M | $19.2M | ||
| Q4 24 | $38.1M | $3.9M | ||
| Q3 24 | $40.6M | $34.7M | ||
| Q2 24 | $43.2M | $4.3M | ||
| Q1 24 | $36.2M | $13.5M |
| Q4 25 | — | $771.2M | ||
| Q3 25 | — | $720.9M | ||
| Q2 25 | — | $815.6M | ||
| Q1 25 | — | $831.5M | ||
| Q4 24 | — | $799.3M | ||
| Q3 24 | — | $815.5M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $843.3M |
| Q4 25 | — | $388.0M | ||
| Q3 25 | — | $375.4M | ||
| Q2 25 | $119.9M | $348.2M | ||
| Q1 25 | $25.0M | $343.7M | ||
| Q4 24 | $-456.0K | $336.5M | ||
| Q3 24 | $-23.5M | $335.8M | ||
| Q2 24 | $-31.2M | $327.5M | ||
| Q1 24 | $-31.7M | $327.1M |
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.3B | ||
| Q2 25 | $175.1M | $5.4B | ||
| Q1 25 | $98.5M | $5.4B | ||
| Q4 24 | $120.5M | $5.4B | ||
| Q3 24 | $139.0M | $5.7B | ||
| Q2 24 | $159.2M | $6.6B | ||
| Q1 24 | $184.7M | $7.1B |
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 1.92× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.42× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-4.5M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.5M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | $-15.8M | $3.3M | ||
| Q1 25 | $-21.0M | $16.0M | ||
| Q4 24 | $-19.9M | $4.4M | ||
| Q3 24 | $-20.7M | $14.7M | ||
| Q2 24 | $-19.5M | $-7.5M | ||
| Q1 24 | $-26.0M | $17.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | -0.89× | 0.62× | ||
| Q4 24 | -1.05× | 0.29× | ||
| Q3 24 | -3.61× | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NREF
Segment breakdown not available.
